MILELONGE

MILELONGE (Chongqing Milelonge Biopharmaceutical Co., Ltd.) is an innovative high-tech biopharmaceutical enterprise focusing on the research, production, and sales of advanced pharmaceutical products. The Milelonge Chengdu Marketing Center and independent drug research and development center are located in Chengdu, Sichuan Province (under construction), while the production base, covering over 250 mu, is located in Chongqing. The company plans to establish four sales branches in Beijing, Shanghai, Guangzhou, and Wuhan. Milelonge holds the production, operation, and sales rights for the NMPA-approved Class 1 new drug, Hiphorfin, used in tumor-PDT treatment. As of 2022, Hiphorfin photodynamic therapy has covered 29 provinces in China, with a total of 388 key tertiary hospitals, teaching hospitals, and cancer specialty hospitals developed cumulatively, along with more than 200 other level hospitals, totaling over 600.